Mangiameli Giuseppe, Cioffi Ugo, Testori Alberto
Division of Thoracic Surgery, IRCCS Humanitas Research Hospital, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Front Oncol. 2022 May 27;12:858242. doi: 10.3389/fonc.2022.858242. eCollection 2022.
Lung cancer (LC) is the second most commonly diagnosed cancer and the primary cause of cancer death worldwide in 2020. LC treatment is associated with huge costs for patients and society; consequently, there is an increasing interest in the prevention, early detection with screening, and development of new treatments. Its surgical management accounts for at least 90% of the activity of thoracic surgery departments. Surgery is the treatment of choice for early-stage non-small cell LC. In this article, we discuss the state of the art of thoracic surgery for surgical management of LC. We start by describing the milestones of LC treatment, which are lobectomy and an adequate lymphadenectomy, and then we focus on the traditional and innovative minimally invasive surgical approaches available: video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS). A brief overview of the innovation and future perspective in thoracic surgery will close this mini-review.
肺癌（LC）是第二大常见诊断癌症，也是2020年全球癌症死亡的主要原因。肺癌治疗给患者和社会带来巨大成本；因此，人们对预防、通过筛查进行早期检测以及开发新疗法的兴趣与日俱增。其外科治疗至少占胸外科科室业务活动的90%。手术是早期非小细胞肺癌的首选治疗方法。在本文中，我们讨论肺癌外科治疗的胸外科技术现状。我们首先描述肺癌治疗的里程碑，即肺叶切除术和充分的淋巴结清扫术，然后重点介绍现有的传统和创新微创手术方法：电视辅助胸腔镜手术（VATS）和机器人辅助胸腔镜手术（RATS）。本文将简要概述胸外科的创新和未来展望，以此结束这篇小型综述。
